The FlexShares Quality Dividend Index Fund (QDF) promises steady income through quality screens, but its substantial allocation to technology stocks—making up one-third of the portfolio—may reshape risk expectations for investors, particularly retirees seeking stability.
As tech giants design their own AI processors, Broadcom's design expertise and TSMC's manufacturing might are creating a lucrative second front in the semiconductor boom, diversifying the winners beyond the GPU market leader.
Global commodity markets opened the new week and month deep in negative territory, with the energy sector plummeting an average of 7.3% and grains facing headwinds from shifting trade flows and seasonal pressures.
A new study highlights a persistent gap between finance and cybersecurity leaders on strategic alignment, risk measurement, and investment priorities, despite widespread recognition of cyber threats.
A couple approaching retirement with $1 million in savings and $42,000 in expected Social Security benefits questions if a $90,000 annual budget is feasible. Financial experts weigh the critical factors—from tax implications to withdrawal rates—that will determine the sustainability of their plan.
From delivering pizzas to building a global sportswear empire, Ben Francis's journey to a $1.4 billion net worth is a modern business fable. Yet, in a candid podcast interview, the Gymshark CEO argues that equating self-worth with wealth is a 'wildly unproductive way to live,' offering a rare glimpse into the mindset behind the paper fortune.
A new report highlights how small and medium-sized businesses are leveraging AI, hyper-personalization, and sustainable practices not just to adapt, but to lead in a rapidly evolving marketplace.
While Legend Biotech's CAR-T therapy Carvykti missed Q4 sales estimates, prompting mixed analyst reactions, some firms emphasize its curative potential and view the stock's recent decline as a strategic entry point for investors.
Following the FDA's decision to remove the clinical hold on Intellia's Nex-Z hATTR-PN trial, analysts at Baird and H.C. Wainwright have significantly raised their price targets for the CRISPR gene-editing pioneer, citing reduced regulatory risk and a clearer path forward.
Clear Street downgrades Janux Therapeutics (JANX) to Hold, slashing its price target amid concerns over a lack of durability data for its lead candidate JANX007 and rising competitive pressures, despite a recent major collaboration deal with Bristol Myers Squibb.
Goldman Sachs has downgraded MoonLake Immunotherapeutics (MLTX) to Sell, highlighting the failed VELA-2 trial endpoint and persistent approval risks for its key drug, sonelokimab, despite a competing firm's more bullish outlook.
A New York graduate's pledge to repay her parents' student loans is tested after they finance a luxury vehicle, sparking a fierce debate over financial responsibility and moral obligation in the shadow of America's student debt crisis.
CFOs are no longer just funders of AI experiments but central architects of its enterprise-wide deployment, navigating a critical shift from promise to production.
Gold and silver prices tumbled from recent highs following the Fed chair nomination, prompting analysts to debate whether the sell-off marks a healthy correction or a shift in the long-term hedge narrative.
Three decades after its birth, New York's Silicon Alley has matured into a distinct tech ecosystem, anchored by profitability, cross-industry ties, and resilience through multiple booms and busts.
Once considered a win-win solution, transforming closed landfills into solar farms faces a complex reality of high costs, regulatory hurdles, and site-specific challenges, even as demand for clean energy and affordable power surges.
Seventeen-year-old Hailey Buzbee vanished after leaving her Vermillion home in early January. Authorities now believe she is deceased and have arrested a man she met through online gaming, though murder charges have not yet been filed.
Analysts at Stifel have raised their price target for Nurix Therapeutics (NRIX) to $35, maintaining a Buy rating ahead of anticipated 2026 clinical milestones for its lead asset, bexobrutinib. The move comes as Wells Fargo also adjusted its target, highlighting divergent near-term views but shared long-term optimism for the biotech firm.
TD Cowen reaffirms its Buy rating on Dynatrace (DT) while adjusting its price target, anticipating stronger-than-expected performance driven by its new AI-powered observability platform, Dynatrace Intelligence.
The renewable energy firm's latest quarterly results, described as a 'beat and raise,' have prompted major banks to lift their valuations, signaling strong confidence in its growth trajectory within the clean energy sector.
